• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

4.930 -0.380 (-7.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 Next >
News headline image
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
March 05, 2026
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Leadership Changes
December 15, 2025
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference
November 12, 2025
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 06, 2025
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
October 23, 2025
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in September Investor Conferences
September 02, 2025
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
August 07, 2025
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera
June 12, 2025
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 08, 2025
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
May 06, 2025
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
March 05, 2025
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
February 27, 2025
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
February 13, 2025
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
December 09, 2024
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
November 18, 2024
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 14, 2024
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
November 13, 2024
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
August 27, 2024
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 15, 2024
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
June 27, 2024
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
June 24, 2024
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
June 20, 2024
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Present at Jefferies Global Healthcare Conference
May 30, 2024
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
May 16, 2024
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
April 30, 2024
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
April 29, 2024
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
April 08, 2024
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
March 13, 2024
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
March 13, 2024
From Silence Therapeutics plc
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap